Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | MTTP | P55157 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101665 | 0.94 | GAA (0.50) | RAB9AGAANPSR1TRPV4SMN1; SMN2 | |
| SCHEMBL3496734 | 0.88 | TMPRSS4 (0.56) | GAANPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL13698751 | 0.87 | TMPRSS4 (0.55) | RAB9AGAANPSR1SMN1; SMN2POLB | |
| SCHEMBL6102756 | 0.86 | POLB (0.52) | RAB9AGAANPSR1SMN1; SMN2LMNA | |
| SCHEMBL3498301 | 0.85 | EPHX1 (0.49) | RAB9AGAANPSR1TRPV4SMN1; SMN2 | |
| SCHEMBL3498004 | 0.83 | KMT2A (0.52) | RAB9AGAANPSR1SMN1; SMN2MAPT | |
| SCHEMBL6102718 | 0.82 | MAOB (0.47) | GAANPSR1TRPV4SMN1; SMN2LMNA | |
| SCHEMBL6101727 | 0.82 | KMT2A (0.48) | RAB9AGAANPSR1SMN1; SMN2LMNA | |
| SCHEMBL6102715 | 0.82 | P2RX1 (0.46) | GAANPSR1TRPV4SMN1; SMN2LMNA | |
| SCHEMBL6101202 | 0.82 | GAA (0.42) | GAANPSR1TRPV4SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | RAB9A 3734/4885GAA 1806/4885NPSR1 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.